10 May 2018 07:00
10 May 2018
IXICO plc
("IXICO" or the "Company")
IXICO announces expansion of contracts with two biopharmaceutical companies
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed amendments to current contracts which expand the clinical trial services provided to two biopharmaceutical companies. The change orders have increased the combined contracts value by £0.5m or c24% to £2.35m.
These changes reflect an expansion in the scope of IXICO's PET and MRI neuroimaging clinical trial services, with IXICO providing additional specialist services during the contract period. The Phase II study contracts in Alzheimer's disease and Huntington's disease were previously announced in July and September 2017, respectively. The scope of services that IXICO provides can be expanded or extended at any time during the life of a clinical trial, so change orders can occur during the course of multi-year contracts.
Giulio Cerroni, Chief Executive Officer of IXICO, said: "We are delighted to announce the expansion of these two contracts. This underscores the importance of working closely with our biopharmaceutical clients, particularly during the initial phase of a contract, to maximise the value our specialist technologies and services can provide".
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
|
|
Shore Capital (Nomad and Broker) Edward Mansfield/Anita Ghanekar | Tel: +44 20 7408 4090 |
|
|
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
Ixico (IXI)